CJC-1295 + Ipamorelin: Why People Pair Them

The CJC-1295 plus ipamorelin stack pairs a GHRH analog with a ghrelin-receptor secretagogue so the two pathways that drive growth-hormone (GH) release work together for a theoretically larger GH pulse. That rationale is mechanistic, not proven: there are essentially no published human trials of the combination. Neither peptide is FDA-approved, both are banned in sport by WADA, and they circulate as research chemicals, so this is at most a provider-directed protocol, never a self-prescription cookbook.

What CJC-1295 and ipamorelin each are

Growth-hormone peptides do not supply GH directly. Instead, they prod your own pituitary gland to release more of its own GH, which then drives insulin-like growth factor 1 (IGF-1) production in the liver. Two different mechanisms are at play in this stack.

CJC-1295 is a synthetic analog of growth-hormone-releasing hormone (GHRH), the hypothalamic signal that tells the pituitary to release GH. The version most people mean by "CJC-1295" includes a drug-affinity complex (DAC) that binds albumin in the blood and stretches its half-life to roughly 6 to 8 days, per the original Phase I/II work by Walker and colleagues (2006). A separate, shorter-acting form without DAC, often called modified GRF 1-29, has a half-life closer to 30 minutes and is a distinct compound with different behavior. Our CJC-1295 guide covers that DAC versus no-DAC split in detail.

Ipamorelin is a synthetic pentapeptide that mimics ghrelin and binds the growth-hormone secretagogue receptor (GHSR), a separate trigger for GH release. It is valued in the community for being selective: it stimulates GH with relatively little effect on cortisol, prolactin, or appetite compared with older secretagogues like GHRP-6. Our ipamorelin guide goes deeper on that selectivity and its limits.

Why people pair them: the synergy theory

The pairing rests on a simple idea. CJC-1295 acts on the GHRH receptor while ipamorelin acts on the ghrelin receptor, and these two pathways are thought to amplify each other when triggered together. In mechanistic terms, GHRH increases the amplitude of the GH pulse while the ghrelin mimetic adds a second, complementary push, so the combined release can be larger than either alone.

That is the strongest part of the case, and it is genuinely rooted in how the GH axis works. The weakest part is that the leap from "two pathways can synergize" to "this stack reliably changes your body" is not supported by combination trials in people. There are no published human studies of CJC-1295 plus ipamorelin together. What you find online is mechanism plus anecdote, and anecdote is not evidence of efficacy or safety.

Each component's role in the stack

Component	Class	Receptor target	Proposed role in the stack	Evidence and status
CJC-1295 (with DAC)	GHRH analog	GHRH receptor	Raises GH pulse amplitude; long half-life sustains IGF-1	Limited human Phase I/II data; not FDA-approved; WADA-banned
Ipamorelin	Ghrelin mimetic (GH secretagogue)	GHSR (ghrelin receptor)	Adds a second, selective GH-release trigger	Mostly preclinical; sparse human data; not FDA-approved; WADA-banned
Combination	GHRH + GHRP pairing	Both pathways	Theoretically synergistic, larger GH pulse	No published human combination trials

This table compares claimed roles and evidence strength, not doses. There is no validated human dosing for the combination, and any figures circulating online are community conventions rather than clinical recommendations.

The evidence, honestly

For CJC-1295, the human data is real but thin: the published Phase I/II work showed dose-dependent rises in GH and IGF-1 in healthy adults, but there are no Phase III trials, no approved indication, and no long-term safety data. For ipamorelin, the picture is even more preclinical, with mostly animal data on GH and IGF-1 and only sparse human studies. For the two combined, there is no published human trial at all.

So the honest summary is: raising GH and IGF-1 is plausible based on mechanism and small studies, but whether the stack meaningfully improves recovery, body composition, or anything else in a real person is unproven. Treat the marketing claims with skepticism, and remember that GH peptides are not a shortcut around training, protein, and sleep. For the body-composition angle specifically, see our breakdown of GH peptides for body recomposition.

Regulatory status: not approved, and banned in sport

This is the part the marketing tends to skip. Neither CJC-1295 nor ipamorelin is FDA-approved for any use. As of 2026, a US Pharmacy Compounding Advisory Committee voted against both compounds at its late-2024 meetings, meaning neither has a clear path to 503A compounding eligibility and they are effectively unavailable from licensed compounding pharmacies. They are sold instead as "research chemicals" through unregulated vendors, which are not reviewed for purity, sterility, or dosing accuracy.

Both peptides are also on the WADA Prohibited List under category S2, banned at all times, in and out of competition. If you are a tested athlete, this stack is a sanction waiting to happen. The compounding landscape is genuinely in flux in 2026, so check FDA.gov and your anti-doping organization for current status rather than relying on a forum post.

Common reported uses and why they are off-label

The stack is promoted for body recomposition, recovery, anti-aging, sleep quality, and general GH "optimization." Every one of these is an off-label, unapproved use, because there is no approved indication for either peptide to begin with. People also commonly describe taking the stack on an empty stomach and often before bed, on the logic of aligning with the natural overnight GH surge.

Those timing conventions are community lore, not clinical dosing. They may be harmless, but they are not validated, and they are not a substitute for instructions from a prescriber who knows your situation.

The "before bed, empty stomach" convention is worth unpacking because it shows how community practice fills the vacuum left by missing trials. The body's largest natural GH pulse happens during early deep sleep, so the reasoning is that timing a secretagogue to that window stacks with the natural rhythm, and that food, particularly carbohydrate and the insulin response it triggers, can blunt GH release. That logic is internally consistent and rooted in real physiology. What it is not is a tested protocol with outcome data showing it actually improves results in people. Plausible and proven are different categories, and most of what circulates about this stack lives in the first one.

Safety: what to weigh before anything

GH-axis stimulation is not consequence-free, even when it works as intended. The class risks discussed with GHRH analogs and secretagogues include fluid retention and edema, numbness or tingling consistent with carpal tunnel syndrome, elevated fasting glucose and reduced insulin sensitivity, and a theoretical concern that raising IGF-1 could stimulate the growth of a pre-existing malignancy. That last point is why anyone with a cancer history needs a clinician weighing in before considering any GH-axis agent.

On top of those biological risks sit the sourcing risks. Gray-market peptides can vary in purity and sterility batch to batch, and endotoxin contamination from poor manufacturing can cause fever, rigors, and serious reactions. A legitimate certificate of analysis includes endotoxin (LAL) testing, not just purity by HPLC, but verifying any of this is something a clinician and pharmacist should help with, not something to navigate alone.

What to ask a provider

If you are exploring this with a licensed clinician, useful questions include: Is there any human evidence that this stack helps my specific goal? How would we monitor IGF-1 and fasting glucose? What is my cancer and cardiovascular risk picture? How would product quality be verified? And is there a more established, evidence-backed path to the same goal? A provider experienced in hormonal health, such as an endocrinologist or sports medicine physician, is the right person to answer these, because they are accountable for your care in a way no article can be.

The tracking angle

If a provider does direct a CJC-1295 plus ipamorelin protocol, the practical challenge is running two timing-sensitive peptides without losing the thread. The DAC-versus-no-DAC question changes how often CJC-1295 is dosed, ipamorelin has its own cadence, and you are juggling two vials with their own reconstituted concentrations.

This is exactly where logging earns its keep. Myo keeps both vials and the combined injection cadence in one timeline with reminders, so the stack runs as prescribed instead of from memory. If you are reconstituting from powder, the reconstitution calculator handles the concentration math so you can record an accurate dose. And because the whole point of a GH-peptide protocol is supposed to be a body-composition change, Myo trends fat-versus-lean mass alongside the log, so you can actually see whether anything is moving beyond placebo, the same fat-versus-muscle lens we apply to GLP-1 muscle loss. For more on running on and off phases, see our guide to peptide cycling.

None of that makes an unproven stack proven. It just turns a scattered, hard-to-review routine into organized data your provider can actually use.

References

• Walker RF, et al. CJC-1295, a long-acting growth hormone releasing factor analog, Phase I/II data in healthy adults. J Clin Endocrinol Metab (2006).
• US FDA. Pharmacy Compounding Advisory Committee proceedings and 503A bulks list status, 2024 to 2026. FDA.gov.
• US FDA. July 23 to 24, 2026 Pharmacy Compounding Advisory Committee meeting announcement. FDA.gov.
• World Anti-Doping Agency. 2026 Prohibited List, category S2 (peptide hormones, growth factors, related substances and mimetics). wada-ama.org.